HBV感染母亲新生儿预防接种与母乳喂养*

doi:10.3969/j.issn.1672-5069.2019.01.003

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (1): 6-8.doi: 10.3969/j.issn.1672-5069.2019.01.003

HBV感染母亲新生儿预防接种与母乳喂养^*

王荣明, 江建宁

530021 南宁市广西医科大学第一附属医院感染性疾病科/区域性高发肿瘤早期防治研究教育部重点实验室

收稿日期:2018-11-07 出版日期:2019-01-10 发布日期:2019-01-16
作者简介:王荣明,女,27岁,博士研究生。E-mail：letitbemaxine@163.com
基金资助:
*“十三五”艾滋病和病毒性肝炎等重大传染病防治科技重大专项（编号：2017ZX10202201）; 广西壮族自治区病毒性肝炎防治研究重点实验室开放课题基金项目（编号：GXCDCKL201802）; 区域性高发肿瘤早期防治研究教育部重点实验室自主课题（编号：GKE2018-05）; 通讯作者：江建宁,女,二级教授; 广西医科大学第一附属医院感染性疾病科主任,主任医师,硕士生/博士生导师; 中华医学会肝脏病学分会全国委员,中华医学会感染病学分会全国委员,中国医师协会感染病科分会常务委员,广西医学会理事,广西医学会感染分会主任委员,广西医师协会感染病科分会主任委员,广西医师协会肝病科分会副主任委员,广西性病艾滋病防治协会副会长,广西艾滋病诊疗中心副主任; 《中华肝脏病杂志》、《中华传染病杂志》、《临床肝胆病杂志》、《实用肝脏病杂志》、《中华临床感染病杂志》等审稿专家或编委; 参与5项国家“十一五”、“十二五”和“十三五”国家艾滋病和病毒性肝炎等重大传染病防治科技重大专项等多中心临床研究,主持完成和在研9项广西自然科学基金项目; 在国内外发表论文80余篇,获广西省级科技进步奖二等和三等奖3项,参编专著10余部; E-mail：jjianning@163.com

Evaluation of breastfeeding and neonatal immune inoculation in mother with HBV infection

Wang Rongming, Jiang Jianning.

Key Laboratory of High-Incidence-Tumor Prevention & Treatment,Department of Infectious Diseases,First Affiliated Hospital,Guangxi Medical University,Nanning 530021

Received:2018-11-07 Online:2019-01-10 Published:2019-01-16

摘要/Abstract

关键词: 乙型肝炎, 母乳喂养, 预防接种

Key words: Hepatitis B, Breastfeeding, Immune inoculation

王荣明, 江建宁. HBV感染母亲新生儿预防接种与母乳喂养^*[J]. 实用肝脏病杂志, 2019, 22(1): 6-8.

Wang Rongming, Jiang Jianning.. Evaluation of breastfeeding and neonatal immune inoculation in mother with HBV infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 6-8.

[1] World Health Organization.Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection. World Health Organization,2015.
[2] Singh AE,Plitt SS,Osiowy C,et al.Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. J Viral Hepat,2011,34(7):S19-S20.
[3] Han GR,Cao MK,Zhao W,et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol,2011,55:1215-1221.
[4] Tran TT.Management of hepatitis B in pregnancy:weighing the options. Cleve Clin J Med,2009,76(Suppl 3):S25.
[5] Han L,Zhang HW,Xie JX,et al.A Meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol,2011,17(38):4321-4333.
[6] Pol S,Corouge M,Fontaine H.Hepatitis B virus infection and pregnancy. Clin Res Hepatol Gastroenterol,2011,35(10):618-622.
[7] Chen X,Chen J,Wen J,et al.Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus. Plos One,2013,8(1):e55303.
[8] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-Ⅴ-ⅩⅩⅢ.
[9] Sarin SK,Kumar M,Lau GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int,2016,10(1):1-98.
[10] Lampertico P,Agarwal K,Berg T,et al.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370-398.
[11] Terrault NA,Lok AS,Mcmahon BJ,et al.Update on prevention,diagnosis,and treatment and of chronic hepatitis B:AASLD 2018 hepatitis B guidance. Hepatology,2018,67(4):1560-1599.
[12] Chen H,Lee C,Chang C,et al.Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology,2015,62(2):375-386.
[13] Greenup AJ,Tan PK,Nguyen V,et al.Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol,2014,61(3):502-507.
[14] Pan CQ,Duan Z,Dai E,et al.Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med,2016,374(24):2324-2334.
[15] 吴晓莉,江建宁,苏明华,等. 核苷(酸)类似物阻断HBV母婴传播的效果及安全性. 山东医药,2015,23(6):21-23.
[16] Ehrhardt S,Xie C,Guo N,et al.Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis,2015,60(2):275-278.
[17] Nguyen V,Tan PK,Greenup AJ,et al.Anti-viral therapy for prevention of perinatal HBV transmission:extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther,2014,39(10):1225-1234.
[18] Wen WH,Huang CW,Chie WC,et al.Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection. Hepatology,2016,64(5):1451-1461.
[19] Mirochnick M,Taha T,Kreitchmann R,et al.Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr,2014,65(1):33-41.
[20] Jao J,Abrams EJ,Phillips T,et al.In utero tenofovir exposure is not associated with fetal long bone growth. Clin Infect Dis,2016,15(12):1604-1609.
[21] Siberry GK,Jacobson DL,Kalkwarf HJ,et al.Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis,2015,61(6):996-1003.
[22] Jacobson DL,Patel K,Williams PL,et al.Growth at 2 years of age in HIV-exposed uninfected children in the United States by trimester of maternal antiretroviral initiation. Pediatr Infect Dis,2017,36(2):189-197.
[23] Hu Y,Wu Q,Xu B,et al.Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants. Vaccine,2008,26(48):6064-6067.
[24] Bruce MG,Bruden D,Hurlburt D,et al.Antibody levels and protection after hepatitis B vaccine:Results of a 30-year follow-up study and response to a booster dose. J Infect Dis,2016,214(1):16-22.
[25] Zou H,Chen Y,Duan Z,et al.Protective effect of hepatitis B vaccine combined with two-dose hepatitis B immunoglobulin on infants born to HBsAg-positive mothers. Plos One,2011,6(10):e26748.
[26] Chen HL,Lin LH,Hu FC,et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology,2012,142(4):773-781.e2.

HBV感染母亲新生儿预防接种与母乳喂养^*

Evaluation of breastfeeding and neonatal immune inoculation in mother with HBV infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[7]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[8]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[9]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[10]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[11]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[12]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[13]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[14]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[15]	陈嵘, 黄美玲, 凌雪梅, 林小红, 曾俊, 黎云, 夏建红. 替比夫定联合HBIG和乙肝疫苗阻断HBV母婴传播临床效果分析*[J]. 实用肝脏病杂志, 2019, 22(5): 752-753.